ASIA-PACIFIC ORTHOBIOLOGICS MARKET FORECAST 2017-2025
KEY FINDINGS
The Asia Pacific orthobiologics market is expected to grow $2590 million by 2025. The market growth is expected at the CAGR of 7.09% in the forecast period. For the market study, the base year considered is 2016. Growing need for orthobiologics products in the region is up surging the growth of the Asia-Pacific orthobiologics market.
MARKET INSIGHTS
The Asia Pacific orthobiologics market is segmented on the basis of end-user, application, product, and geography. End-user market segmented into hospitals and clinics. The application segment is further classified into spinal fusion, trauma repair, and reconstructive surgery. The Asia-Pacific market of orthobiologics by product is further segmented into demineralized bone matrix (DBM), Bone morphogenetic protein (BMP), viscosupplementation, synthetic bone graft substitutes, and stem cell therapy. The Asia-Pacific orthobiologics market of geography is further segmented into India, China, Japan, Australia and rest of Asia-Pacific. Demand for biological implants is increasing then the mechanical implant and rise in the awareness of orthobiologics benefits is proliferating the growth of the market in this region.
COMPETETIVE INSIGHTS
Major players for the Orthobiologics market are Integra Life sciences Holding Corporation, Bioventus, Johnson& Johnson, DePuy Inc. (Acquired by Johnson and Johnson), Zimmer Biomet Inc., Exatech Inc., Mölnlycke Health Care AB, Nuvasive Inc., Globus Medical Inc., Stryker Corporation, RTI Surgical, Medtronic Inc., and Sanofi.
The Asia Pacific orthobiologics market is expected to grow $2590 million by 2025. The market growth is expected at the CAGR of 7.09% in the forecast period. For the market study, the base year considered is 2016. Growing need for orthobiologics products in the region is up surging the growth of the Asia-Pacific orthobiologics market.
MARKET INSIGHTS
The Asia Pacific orthobiologics market is segmented on the basis of end-user, application, product, and geography. End-user market segmented into hospitals and clinics. The application segment is further classified into spinal fusion, trauma repair, and reconstructive surgery. The Asia-Pacific market of orthobiologics by product is further segmented into demineralized bone matrix (DBM), Bone morphogenetic protein (BMP), viscosupplementation, synthetic bone graft substitutes, and stem cell therapy. The Asia-Pacific orthobiologics market of geography is further segmented into India, China, Japan, Australia and rest of Asia-Pacific. Demand for biological implants is increasing then the mechanical implant and rise in the awareness of orthobiologics benefits is proliferating the growth of the market in this region.
COMPETETIVE INSIGHTS
Major players for the Orthobiologics market are Integra Life sciences Holding Corporation, Bioventus, Johnson& Johnson, DePuy Inc. (Acquired by Johnson and Johnson), Zimmer Biomet Inc., Exatech Inc., Mölnlycke Health Care AB, Nuvasive Inc., Globus Medical Inc., Stryker Corporation, RTI Surgical, Medtronic Inc., and Sanofi.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. KEY FINDINGS
4. MARKET OVERVIEW
4.1. MARKET DRIVERS
4.1.1. DEMAND FOR SPINAL FUSION SURGERIES
4.1.2. GROWTH IN STRATEGIC PARTNERSHIPS
4.1.3. INCREASE IN ORTHOBIOLOGICS MATERIAL
4.2. RESTRAINTS
4.2.1. STRINGENT GOVERNMENT POLICIES
4.2.2. POST-SURGERY COMPLICATIONS
4.3. OPPORTUNITIES
4.3.1. BONE REGENERATION TECHNOLOGY
4.3.2. LARGER SPEND ON HEALTHCARE
4.4. CHALLENGES
4.4.1. HIGH COST OF SPINAL FUSION SURGERY
4.4.2. PRODUCT SIDE EFFECTS AND FDA SCRUTINY
4.4.3. POOR PERFORMANCE OF BONE GRAFT SUBSTITUTE
5. SEGMENTATION
5.1. BY PRODUCTS
5.1.1. DEMINERALIZED BONE MATRIX (DBM)
5.1.2. ALLOGRAFT
5.1.3. BONE MORPHOGENETIC PROTEIN (BMP)
5.1.4. VISCOSUPPLEMENTATION
5.1.5. SYNTHETIC BONE GRAFT SUBSTITUTES
5.1.6. STEM CELL THERAPY
5.1.7. OTHER PRODUCT MARKET
5.2. BY APPLICATION
5.2.1. SPINAL FUSION
5.2.2. TRAUMA REPAIR
5.2.3. RECONSTRUCTIVE SURGERY
5.2.4. TENDON & LIGAMENT REPAIR MARKET
5.2.5. OTHER APPLICATIONS MARKET
5.3. BY END-USER
5.3.1. HOSPITAL MARKET
5.3.2. CLINICS MARKET
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCES ANALYSIS
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
6.1.3. BARGAINING POWER OF BUYER
6.1.4. BARGAINING POWER OF SUPPLIER
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. PESTEL ANALYSIS
6.3. OPPORTUNITY MATRIX
6.4. VALUE CHAIN ANALYSIS
6.5. VENDOR LANDSCAPE
7. REGIONAL ANALYSIS
7.1. ASIA-PACIFIC ORTHOBIOLOGICS MARKET
7.1.1. INDIA ORTHOBIOLOGICS MARKET
7.1.2. CHINA ORTHOBIOLOGICS MARKET
7.1.3. JAPAN ORTHOBIOLOGICS MARKET
7.1.4. AUSTRALIA ORTHOBIOLOGICS MARKET
7.1.5. ROAPAC ORTHOBIOLOGICS MARKET
8. COMPETITIVE LANDSCAPE
8.1. MARKET SHARE ANALYSIS
8.2. MERGERS & ACQUISITIONS
9. COMPANY PROFILE
9.1. BIOVENTUS
9.1.1. OVERVIEW
9.1.2. PRODUCTS PORTFOLIO
9.1.3. STRATEGIC INITIATIVES
9.1.4. SCOT ANALYSIS
9.2. DEPUY INC (ACQUIRED BY JOHNSON AND JOHNSON)
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. STRATEGIC INITIATIVES
9.2.4. SCOT ANALYSIS
9.2.5. STRATEGIC ANALYSIS
9.3. EXATECH INC
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.3.4. STRATEGIC ANALYSIS
9.4. GLOBUS MEDICAL INC
9.4.1. OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. STRATEGIC INITIATIVES
9.4.4. SCOT
9.4.5. STRATEGIC ANALYSIS
9.5. INTEGRA LIFESCIENCES HOLDING CORPORATION
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. STRATEGIC INITIATIVES
9.5.4. SCOT ANALYSIS
9.5.5. STRATEGIC ANALYSIS
9.6. JOHNSON& JOHNSON
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. STRATEGIC INITIATIVES
9.6.4. SCOT ANALYSIS
9.7. MEDTRONIC INC
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC INITIATIVES
9.7.4. SCOT
9.8. NUVASIVE INC
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. STRATEGIC INITIATIVES
9.8.4. SCOT ANALYSIS
9.8.5. STRATEGIC ANALYSIS
9.9. RTI SURGICAL
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. STRATEGIC INITIATIVES
9.9.4. SCOT ANALYSIS
9.10. SANOFI
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. STRATEGIC INITIATIVES
9.10.4. SCOT ANALYSIS
9.11. STRYKER CORPORATION
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. STRATEGIC INITIATIVES
9.11.4. SCOT ANALYSIS
9.11.5. STRATEGIC ANALYSIS
9.12. ZIMMER BIOMET INC
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. STRATEGIC INITIATIVES
9.12.4. SCOT ANALYSIS
9.12.5. STRATEGIC ANALYSIS
9.13. MÖLNLYCKE HEALTH CARE AB
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. STRATEGIC INITIATIVES
9.13.4. SCOT ANALYSIS
TABLE LIST
TABLE 1 OLDER POPULATION BY AGE GROUP: 1900 TO 2050
TABLE 2 FINANCING FOR ORTHOBIOLOGICS ADVANCEMENT
TABLE 3 POST-SURGERY COMPLICATIONS
TABLE 4 ASIA-PACIFIC ORTHOBIOLOGICS MARKET BY PRODUCTS 2017-2025 ($ MILLIONS)
TABLE 5 DEMINERALIZED BONE MATRIX ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
TABLE 6 ALLOGRAFT ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
TABLE 7 BONE MORPHOGENETIC PROTEIN (BMP) ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
TABLE 8 VISCOSUPPLEMENTATION MARKET 2017-2025 ($ MILLIONS)
TABLE 9 SYNTHETIC BONE GRAFT MARKET 2017-2025 ($ MILLIONS)
TABLE 10 STEM CELL THERAPY MARKET 2017-2025 ($ MILLIONS)
TABLE 11 OTHER PRODUCTS MARKET 2017-2025 ($ MILLIONS)
TABLE 12 ASIA-PACIFIC ORTHOBIOLOGICS MARKET BY APPLICATION 2017-2025 ($ MILLIONS)
TABLE 13 SPINAL FUSION MARKET 2017-2025 ($ MILLIONS)
TABLE 14 TRAUMA REPAIR MARKET 2017-2025 ($ MILLIONS)
TABLE 15 RECONSTRUCTIVE SURGERY MARKET 2017-2025 ($ MILLIONS)
TABLE 16 TENDON & LIGAMENT ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
TABLE 17 OTHER APPLICATIONS ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
TABLE 18 ASIA-PACIFIC ORTHOBIOLOGICS MARKET BY END-USER, 2017-2025 ($ MILLION)
TABLE 19 HOSPITAL ORTHOBIOLOGICS MARKET, 2017-2025 ($ MILLIONS)
TABLE 20 ORTHOBIOLOGICS CLINICS MARKET 2017-2025 ($ MILLIONS)
FIGURES LIST
FIGURE 1 INCREASING DEMAND OF MINIMAL INVASIVE TECHNOLOGIES 2010-2025 ($ MILLION)
FIGURE 2 DEMINERALIZED BONE MATRIX ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 3 ALLOGRAFT ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 4 BONE MORPHOGENIC PROTEIN (BMP) ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 5 VISCOSUPPLEMENTATION ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 6 SYNTHETIC BONE GRAFT ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 7 STEM CELL THERAPY ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 8 ASIA-PACIFIC OTHER PRODUCTS MARKET 2017-2025 ($ MILLION)
FIGURE 9 SPINAL FUSION ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 10 TRAUMA REPAIR ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 11 RECONSTRUCTIVE SURGERY ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 12 TENDON & LIGAMENT ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 13 OTHER APPLICATIONS ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 14 COST OF KNEE REPLACEMENT IN DEVELOPING COUNTRIES IN 2017
FIGURE 15 ORTHOBIOLOGICS HOSPITAL MARKET 2017-2025 ($ MILLIONS)
FIGURE 16 ORTHOBIOLOGICS CLINICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 17 ASIA-PACIFIC ORTHOBIOLOGICS MARKET BY COUNTRY 2016 & 2025
FIGURE 18 POPULATION AGES 65 AND ABOVE IN TOP 3 COUNTRIES IN ASIA-PACIFIC (% OF TOTAL)
FIGURE 19 INDIA ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLION)
FIGURE 20 CHINA ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLION)
FIGURE 21 JAPAN ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLION)
FIGURE 22 AUSTRALIA ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLION)
FIGURE 23 ROAPAC ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLION)
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. KEY FINDINGS
4. MARKET OVERVIEW
4.1. MARKET DRIVERS
4.1.1. DEMAND FOR SPINAL FUSION SURGERIES
4.1.2. GROWTH IN STRATEGIC PARTNERSHIPS
4.1.3. INCREASE IN ORTHOBIOLOGICS MATERIAL
4.2. RESTRAINTS
4.2.1. STRINGENT GOVERNMENT POLICIES
4.2.2. POST-SURGERY COMPLICATIONS
4.3. OPPORTUNITIES
4.3.1. BONE REGENERATION TECHNOLOGY
4.3.2. LARGER SPEND ON HEALTHCARE
4.4. CHALLENGES
4.4.1. HIGH COST OF SPINAL FUSION SURGERY
4.4.2. PRODUCT SIDE EFFECTS AND FDA SCRUTINY
4.4.3. POOR PERFORMANCE OF BONE GRAFT SUBSTITUTE
5. SEGMENTATION
5.1. BY PRODUCTS
5.1.1. DEMINERALIZED BONE MATRIX (DBM)
5.1.2. ALLOGRAFT
5.1.3. BONE MORPHOGENETIC PROTEIN (BMP)
5.1.4. VISCOSUPPLEMENTATION
5.1.5. SYNTHETIC BONE GRAFT SUBSTITUTES
5.1.6. STEM CELL THERAPY
5.1.7. OTHER PRODUCT MARKET
5.2. BY APPLICATION
5.2.1. SPINAL FUSION
5.2.2. TRAUMA REPAIR
5.2.3. RECONSTRUCTIVE SURGERY
5.2.4. TENDON & LIGAMENT REPAIR MARKET
5.2.5. OTHER APPLICATIONS MARKET
5.3. BY END-USER
5.3.1. HOSPITAL MARKET
5.3.2. CLINICS MARKET
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCES ANALYSIS
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
6.1.3. BARGAINING POWER OF BUYER
6.1.4. BARGAINING POWER OF SUPPLIER
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. PESTEL ANALYSIS
6.3. OPPORTUNITY MATRIX
6.4. VALUE CHAIN ANALYSIS
6.5. VENDOR LANDSCAPE
7. REGIONAL ANALYSIS
7.1. ASIA-PACIFIC ORTHOBIOLOGICS MARKET
7.1.1. INDIA ORTHOBIOLOGICS MARKET
7.1.2. CHINA ORTHOBIOLOGICS MARKET
7.1.3. JAPAN ORTHOBIOLOGICS MARKET
7.1.4. AUSTRALIA ORTHOBIOLOGICS MARKET
7.1.5. ROAPAC ORTHOBIOLOGICS MARKET
8. COMPETITIVE LANDSCAPE
8.1. MARKET SHARE ANALYSIS
8.2. MERGERS & ACQUISITIONS
9. COMPANY PROFILE
9.1. BIOVENTUS
9.1.1. OVERVIEW
9.1.2. PRODUCTS PORTFOLIO
9.1.3. STRATEGIC INITIATIVES
9.1.4. SCOT ANALYSIS
9.2. DEPUY INC (ACQUIRED BY JOHNSON AND JOHNSON)
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. STRATEGIC INITIATIVES
9.2.4. SCOT ANALYSIS
9.2.5. STRATEGIC ANALYSIS
9.3. EXATECH INC
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.3.4. STRATEGIC ANALYSIS
9.4. GLOBUS MEDICAL INC
9.4.1. OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. STRATEGIC INITIATIVES
9.4.4. SCOT
9.4.5. STRATEGIC ANALYSIS
9.5. INTEGRA LIFESCIENCES HOLDING CORPORATION
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. STRATEGIC INITIATIVES
9.5.4. SCOT ANALYSIS
9.5.5. STRATEGIC ANALYSIS
9.6. JOHNSON& JOHNSON
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. STRATEGIC INITIATIVES
9.6.4. SCOT ANALYSIS
9.7. MEDTRONIC INC
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC INITIATIVES
9.7.4. SCOT
9.8. NUVASIVE INC
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. STRATEGIC INITIATIVES
9.8.4. SCOT ANALYSIS
9.8.5. STRATEGIC ANALYSIS
9.9. RTI SURGICAL
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. STRATEGIC INITIATIVES
9.9.4. SCOT ANALYSIS
9.10. SANOFI
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. STRATEGIC INITIATIVES
9.10.4. SCOT ANALYSIS
9.11. STRYKER CORPORATION
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. STRATEGIC INITIATIVES
9.11.4. SCOT ANALYSIS
9.11.5. STRATEGIC ANALYSIS
9.12. ZIMMER BIOMET INC
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. STRATEGIC INITIATIVES
9.12.4. SCOT ANALYSIS
9.12.5. STRATEGIC ANALYSIS
9.13. MÖLNLYCKE HEALTH CARE AB
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. STRATEGIC INITIATIVES
9.13.4. SCOT ANALYSIS
TABLE LIST
TABLE 1 OLDER POPULATION BY AGE GROUP: 1900 TO 2050
TABLE 2 FINANCING FOR ORTHOBIOLOGICS ADVANCEMENT
TABLE 3 POST-SURGERY COMPLICATIONS
TABLE 4 ASIA-PACIFIC ORTHOBIOLOGICS MARKET BY PRODUCTS 2017-2025 ($ MILLIONS)
TABLE 5 DEMINERALIZED BONE MATRIX ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
TABLE 6 ALLOGRAFT ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
TABLE 7 BONE MORPHOGENETIC PROTEIN (BMP) ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
TABLE 8 VISCOSUPPLEMENTATION MARKET 2017-2025 ($ MILLIONS)
TABLE 9 SYNTHETIC BONE GRAFT MARKET 2017-2025 ($ MILLIONS)
TABLE 10 STEM CELL THERAPY MARKET 2017-2025 ($ MILLIONS)
TABLE 11 OTHER PRODUCTS MARKET 2017-2025 ($ MILLIONS)
TABLE 12 ASIA-PACIFIC ORTHOBIOLOGICS MARKET BY APPLICATION 2017-2025 ($ MILLIONS)
TABLE 13 SPINAL FUSION MARKET 2017-2025 ($ MILLIONS)
TABLE 14 TRAUMA REPAIR MARKET 2017-2025 ($ MILLIONS)
TABLE 15 RECONSTRUCTIVE SURGERY MARKET 2017-2025 ($ MILLIONS)
TABLE 16 TENDON & LIGAMENT ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
TABLE 17 OTHER APPLICATIONS ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
TABLE 18 ASIA-PACIFIC ORTHOBIOLOGICS MARKET BY END-USER, 2017-2025 ($ MILLION)
TABLE 19 HOSPITAL ORTHOBIOLOGICS MARKET, 2017-2025 ($ MILLIONS)
TABLE 20 ORTHOBIOLOGICS CLINICS MARKET 2017-2025 ($ MILLIONS)
FIGURES LIST
FIGURE 1 INCREASING DEMAND OF MINIMAL INVASIVE TECHNOLOGIES 2010-2025 ($ MILLION)
FIGURE 2 DEMINERALIZED BONE MATRIX ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 3 ALLOGRAFT ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 4 BONE MORPHOGENIC PROTEIN (BMP) ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 5 VISCOSUPPLEMENTATION ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 6 SYNTHETIC BONE GRAFT ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 7 STEM CELL THERAPY ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 8 ASIA-PACIFIC OTHER PRODUCTS MARKET 2017-2025 ($ MILLION)
FIGURE 9 SPINAL FUSION ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 10 TRAUMA REPAIR ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 11 RECONSTRUCTIVE SURGERY ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 12 TENDON & LIGAMENT ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 13 OTHER APPLICATIONS ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 14 COST OF KNEE REPLACEMENT IN DEVELOPING COUNTRIES IN 2017
FIGURE 15 ORTHOBIOLOGICS HOSPITAL MARKET 2017-2025 ($ MILLIONS)
FIGURE 16 ORTHOBIOLOGICS CLINICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 17 ASIA-PACIFIC ORTHOBIOLOGICS MARKET BY COUNTRY 2016 & 2025
FIGURE 18 POPULATION AGES 65 AND ABOVE IN TOP 3 COUNTRIES IN ASIA-PACIFIC (% OF TOTAL)
FIGURE 19 INDIA ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLION)
FIGURE 20 CHINA ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLION)
FIGURE 21 JAPAN ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLION)
FIGURE 22 AUSTRALIA ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLION)
FIGURE 23 ROAPAC ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLION)
